Frequency Therapeutics Inc (KRRO) - Total Liabilities
Based on the latest financial reports, Frequency Therapeutics Inc (KRRO) has total liabilities worth $62.52 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Frequency Therapeutics Inc to assess how effectively this company generates cash.
Frequency Therapeutics Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Frequency Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Frequency Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Frequency Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Frequency Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AleAnna, Inc. Class A Common Stock
NASDAQ:ANNA
|
USA | $41.73 Million |
|
Clarus Corp
NASDAQ:CLAR
|
USA | $57.27 Million |
|
Scully Royalty Ltd
NYSE:SRL
|
USA | $124.67 Million |
|
HLS Therapeutics Inc
TO:HLS
|
Canada | CA$78.49 Million |
|
Adda Corporation
TWO:3071
|
Taiwan | NT$1.95 Billion |
|
Ruentex Materials Co Ltd
TW:8463
|
Taiwan | NT$6.94 Billion |
|
EcoFirst Consolidated Bhd
KLSE:3557
|
Malaysia | RM463.23 Million |
|
Chateau International Development Co Ltd
TW:2722
|
Taiwan | NT$930.14 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Frequency Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see KRRO market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.63 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Frequency Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Frequency Therapeutics Inc (2017–2024)
The table below shows the annual total liabilities of Frequency Therapeutics Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $65.83 Million | +27.19% |
| 2023-12-31 | $51.75 Million | -70.05% |
| 2022-12-31 | $172.77 Million | +216.82% |
| 2021-12-31 | $54.53 Million | -24.50% |
| 2020-12-31 | $72.23 Million | +29.31% |
| 2019-12-31 | $55.86 Million | -37.28% |
| 2018-12-31 | $89.06 Million | +80.17% |
| 2017-12-31 | $49.43 Million | -- |
About Frequency Therapeutics Inc
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oli… Read more